Cordlife GroupCLIFF 33 PB Ratio is 0.48 as of Jun. 27, 2026, which is 35% below its 10-year median of 0.74. GuruFocus rates CLIFF with a GF Score™ of 33/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Cordlife Group ranks better than 96.94% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), Cordlife Group's share price is $0.15048. Cordlife Group's Book Value per Share for the quarter that ended in Mar. 2026 was $0.31. Hence, Cordlife Group's PB Ratio of today is 0.48.
Good Sign:
Cordlife Group Ltd stock PB Ratio (=0.32) is close to 1-year low of 0.3.
The historical rank and industry rank for Cordlife Group's PB Ratio or its related term are showing as below:
CLIFF'
s PB Ratio Range Over the Past 10 Years
Min: 0.23 Med: 0.74 Max: 2.65
Current: 0.32
During the past 13 years, Cordlife Group's highest PB Ratio was 2.65. The lowest was 0.23. And the median was 0.74.
CLIFF's PB Ratio is ranked better than 96.94% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs CLIFF: 0.32
During the past 3 years, the average Book Value Per Share Growth Rate was -8.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -4.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -2.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Cordlife Group was 44.90% per year. The lowest was -8.10% per year. And the median was 1.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cordlife Group PB Ratio Related Terms
Cordlife Group PB Ratio Historical Data
* Premium members only.
The historical data trend for Cordlife Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Cordlife Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cordlife Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Cordlife Group's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cordlife Group (CLIFF) has a PB Ratio of 0.48 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cordlife Group and its competitors. This is 35% below median its historical median of 0.74. Over the past decade, Cordlife Group's PB Ratio has ranged from 0.23 to 2.65. According to the industry distribution chart, Cordlife Group ranks #6 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 3.1%.
Is Cordlife Group's PB Ratio too high?
Cordlife Group's current PB Ratio of 0.48 is 35% below median its 10-year median of 0.74. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 2.65. The Medical Diagnostics & Research industry median PB Ratio is 2.05. Cordlife Group's value of 0.48 is 76.6% below this industry median. Based on the distribution chart, Cordlife Group ranks #6 out of 196 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cordlife Group has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #6 out of 196 companies for PB Ratio. This places Cordlife Group in the top 3% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.05. Cordlife Group's value of 0.48 is 76.6% below this benchmark. Historically, Cordlife Group's own PB Ratio has ranged from 0.23 to 2.65 over the past decade. While the company's 10-year median is 0.74 vs. the industry median of 2.05, Cordlife Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cordlife Group's current PB Ratio of 0.48 is 76.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cordlife Group and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cordlife Group's current PB Ratio is 0.48, which is 35% below median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.15 — trading 88.1% above its estimated fair value. The current PB Ratio is 0.48, which is 35% below median its 10-year median of 0.74 and 76.6% below the Medical Diagnostics & Research industry median of 2.05. Cordlife Group's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current PB Ratio is 0.48 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued.
The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08.
GuruFocus considers Cordlife Group to be Significantly Overvalued.
Key valuation signals for CLIFF:
PB Ratio: 0.48 (35% below median its 10-year median of 0.74)
GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
Industry Position: 76.6% below the Medical Diagnostics & Research median (#6 of 196)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
33GF Score
Get the complete analysis for CLIFF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
